This will put Merck in direct competition both with generics firms, such as Teva of Israel, and with biotech giants, such as Amgen, which make the expensive products that biosimilars hope to replace.

• 默克将因此与仿制药公司（比如以色列的Teva）和生物技术业的巨头（比如Amgen）直接竞争，生物仿制品有望替代这些公司生产的昂贵产品。